“Global Study Reveals Essential Medicines Less Affordable in Poorer Nations Despite Lower Prices: Patients Face Disproportionate Cost Burdens”

The recent global study published in JAMA Health Forum in 2025 reveals a critical disparity in the affordability of essential medicines between low- and middle-income countries (LMICs) and wealthier nations. Despite nominal prices appearing lower in poorer countries, an adjustment for the local purchasing power exposes a greater financial burden on patients in these regions, underscoring a pressing public health challenge.​

Key Findings and Developments

The study, involving researchers from Brown University and the London School of Economics, analyzed the prices and consumption of approximately 550 essential medicines across 72 countries in 2022. While higher-income nations listed higher absolute prices, patients in poorer nations faced less affordability once prices were contextualized by local currency purchasing power. For instance, drug prices in India, though low in nominal terms, ranked in the middle range when adjusted, marking an elevated burden for income levels.​

The data shows stark usage disparities: Europe averaged 634 annual medicine doses per capita, while Southeast Asia averaged just 143, reflecting differences in access and healthcare system effectiveness. Medicines for mental health and cardiovascular disease topped the cost list, whereas treatments for hepatitis B and C ranked comparatively cheaper. The affordability crisis is striking in examples such as the hepatitis B/HIV drug tenofovir disoproxil in India, where minimum wage workers must labor about 10 days to afford a one-month supply.​

Expert Perspectives

Dr. Olivier J. Wouters, lead author and an expert in global health economics at Brown University, emphasizes the critical need for equitable pricing policies: “Lower nominal prices in poorer countries do not translate to affordability. The disproportionate cost burden on patients requires urgent global strategies to improve access”.​

Independent experts highlight that high out-of-pocket payments in LMICs further exacerbate inequitable access. Unlike wealthier countries, where drug subsidies limit patient costs, many poorer countries see patients shouldering the full price, which amounts to a severe barrier to treatment adherence and overall health outcomes.​

Context and Background

Essential medicines, as defined by the World Health Organization (WHO), are drugs that satisfy priority healthcare needs and are fundamental to health system functioning. Despite their importance, access remains uneven, especially in LMICs, where availability can be as low as 41%, compared to up to 80% in richer countries. The WHO’s Model List of Essential Medicines informed the study’s medicine selection, excluding some categories like HIV, TB, and malaria treatments typically procured through special international programs.​

The gap in affordability is intertwined with wider socioeconomic inequities. Low-income populations repeatedly face challenges such as large out-of-pocket payments, limited insurance coverage, and geographic disparities in drug availability. Additionally, markups and taxes on medicines in some countries further drive costs higher.​

Public Health Implications

This affordability disparity threatens the global commitment to universal health coverage and the Sustainable Development Goals targeting equitable healthcare access by 2030. High medicine costs in LMICs impede adherence to lifesaving treatments for chronic and infectious diseases, potentially leading to avoidable morbidity and mortality.​

Addressing these inequities requires multifaceted strategies including international price negotiations, generic drug promotion, local production scaling, and stronger regulatory frameworks. Governments and global health organizations must collaborate to establish more equitable pricing models that consider local economic realities and purchasing power to ensure medicines are within reach for all patients.​

Potential Limitations and Counterarguments

While this study provides comprehensive global insights, it excludes some critical medicine classes and does not capture informal or out-of-market pricing, which may affect real-world affordability. Differences in insurance and subsidy coverage across countries also complicate direct price comparisons. Furthermore, medicine availability variations within countries, between urban and rural areas, underline the complexity of access that extends beyond price alone

For health-conscious consumers and patients, understanding that medicine prices alone do not indicate affordability is vital. Advocating for transparent pricing and support mechanisms can help reduce personal financial strain. Health professionals can use these insights to push for policy reforms and support patient assistance programs. Ultimately, this study calls for attention to economic barriers impacting treatment adherence and health outcomes worldwide.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References